Sun Pharma elevates Aalok Shanghvi to the board, appoints Rolf Hoffmann as ID

Sun Pharma has elevated Aalok Shanghvi to the board of directors for a five-year term beginning June 1, 2023. Shanghvi is the executive vice president in charge of emerging markets, worldwide generic research and development, global generic business development, and API.

He started with Sun in 2006 and has worked in marketing, R&D, project management, purchasing, and communications. He took over the emerging markets business, which spans 80 countries in Africa, the Middle East, Asia, Eastern Europe, the Commonwealth of Independent States, and Latin America, in 2010. He was then in charge of global generic R&D, global generic business development, and API. Sun Pharma’s board of directors approved the appointment of Rolf Hoffmann as an independent director on 14th June 2023.

He has over 29 years of expertise managing the top 50 global markets with complete profit and loss responsibility and cross-functional accountability. Hoffman has been with Eli Lilly for 17 years, including in-country management, international regional management, and headquarters global executive positions. In his numerous roles, he constructed a global regulatory and governmental affairs network and developed comprehensive commercial capabilities for all geographies, including alliances, joint ventures, and organic growth plans.